CTSO: CytoSorbents reports preliminary 4th quarter and 2024 financial results which showed impressive growth in the core international business that exceeded our expectations.

448 Views04 Jan 2025 04:00

Issuer-paid

CytoSorbents is commercializing its E.U. approved CytoSorb blood purification technology to treat life-threatening conditions in the intensive...

What is covered in the Full Insight:

SUMMARY

(Sign Up to Access)

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Full Insight

(Paid Plans Only, 27-minute read)

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream